860549P

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z))

Avanti Research^™ - A Croda Brand 860549P, powder

• Synonym(e): D-glucosyl-β-1,1′-N-nervonoyl-D-erythro-sphingosine
• Empirische Formel (Hill-System): C₄₈H₉₁NO₈
• CAS-Nummer: 887907-50-8
• Molekulargewicht: 810.24
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Form: powder
• Verpackung: pkg of 1 × 5 mg (860549P-5mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 860549P
• Lipid-Typ: sphingolipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: [H][C@](/C=C/CCCCCCCCCCCCC)(O)[C@@]([H])(NC(CCCCCCCCCCCCC/C=C\CCCCCCCC)=O)CO[C@H](O1)[C@H](O)[C@@H](O)[C@@H]([C@H]1CO)O

Beschreibung

Allgemeine Beschreibung

β-Glucosylceramides or glucocerebrosides (GlcCers) are synthesized from the glycosphingolipids by β-GlcCer synthase. They are synthesized in Golgi and endoplasmic reticulum and localized in the cytosolic side of cell membrane. GlcCers are omnipresent.

Anwendung

C24:1 Glucosyl(β) Ceramide (d18:1/24:1(15Z)) may be used:

• as a standard hexosylceramide for hydrophilic interaction chromatography-based liquid chromatography mass spectroscopy
• to test its nuclear factor of activated T-cells (NFAT) activation
• in human natural killer T (NKT) cell potency assays

Biochem./physiol. Wirkung

β-Glucosylceramides (β-GlcCer) levels are elevated inlevels in Gaucher′s disease, due to the deficiency of β-glucosidase. β-GlcCer participates in the inflammatory and acquired immune responses by binding mincle on myeloid cells and has immunostimulatory activity.

Verpackung

5 mL Amber Glass Screw Cap Vial (860549P-5mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids